Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 381

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit

Open access
Noshi, Takeshi, Kitano, Mitsutaka, Taniguchi, Keiichi, Yamamoto, Atsuko, Omoto, Shinya, Baba, Keiko, Hashimoto, Takashi, Ishida, Kayo, Kushima, Yukihiro, Hattori, Kazunari, Kawai, Makoto, Yoshida, Ryu, Kobayashi, Masanori, Yoshinaga, Tomokazu, Sato, Akihiko, Okamatsu, Masatoshi, Sakoda, Yoshihiro, Kida, Hiroshi, Shishido, Takao, Naito, Akira·2018·Antiviral Research

Abstract

Cap-dependent endonuclease (CEN) resides in the PA subunit of the influenza virus and mediates the critical "cap-snatching" step of viral RNA transcription, which is considered to be a promising anti-influenza target. Here, we describe in vitro characterization of a novel CEN inhibitor, baloxavir acid (BXA), the active form of baloxavir marboxil (BXM). BXA inhibits viral RNA transcription via selective inhibition of CEN activity in enzymatic assays, and inhibits viral replication in infected cells without cytotoxicity in cytopathic effect assays. The antiviral activity of BXA is also confirmed in yield reduction assays with seasonal type A and B viruses, including neuraminidase inhibitor-resistant strains. Furthermore, BXA shows broad potency against various subtypes of influenza A viruses (H1N2, H5N1, H5N2, H5N6, H7N9 and H9N2). Additionally, serial passages of the viruses in the presence of BXA result in isolation of PA/I38T variants with reduced BXA susceptibility. Phenotypic and genotypic analyses with reverse genetics demonstrate the mechanism of BXA action via CEN inhibition in infected cells. These results reveal the in vitro characteristics of BXA and support clinical use of BXM to treat influenza.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.antiviral.2018.10.008

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Cited by

See all 381

Metadata

Authors
Noshi, T., Kitano, M., Taniguchi, K., Yamamoto, A., Omoto, S., Baba, K., Hashimoto, T., Ishida, K., Kushima, Y., Hattori, K., Kawai, M., Yoshida, R., Kobayashi, M., Yoshinaga, T., Sato, A., Okamatsu, M., Sakoda, Y., Kida, H., Shishido, T., & Naito, A.
Venue
Antiviral Research
Publisher
Elsevier BV
Published
2018-12
Volume
160
Pages
109-117
ISSN
0166-3542 (ISSN-L)
OpenAlex
W2897317761
Cited by
381
References
20
FWCI
27.78
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit. https://app.cochat.ai/papers/10.1016/j.antiviral.2018.10.008
The paper
Noshi, T., Kitano, M., Taniguchi, K., Yamamoto, A., Omoto, S., Baba, K., Hashimoto, T., Ishida, K., Kushima, Y., Hattori, K., Kawai, M., Yoshida, R., Kobayashi, M., Yoshinaga, T., Sato, A., Okamatsu, M., Sakoda, Y., Kida, H., Shishido, T., & Naito, A. (2018). In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit. Antiviral Research. https://doi.org/10.1016/j.antiviral.2018.10.008

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.